Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 2242 |
| PDBID: | 6GKD |
| Chains: | N_L |
| Organism: | Homo sapiens, Lama glama |
| Method: | XRD |
| Resolution (Å): | 2.99 |
| Reference: | 10.1038/s41467-019-10714-y |
| Antibody | |
| Antibody: | G3a Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Cystic fibrosis transmembrane conductance regulator |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Chain: N
Mutation: NULL
| >6GKD_N|Chain C, F[auth H], I[auth K], L[auth N], O[auth Q], R[auth T]|Nanobody G3a|Lama glama (9844) QVQLQESGGGLVQAGGSLRLSCTASGRAFSWYVMGWFRQAPGKEREFVATVSGNGSRRDYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASSTYYYTDPEKYDYWGQGTQVTVSSAAAHHHHHHGAAEQKLISEEDLNGAA |
Antigen
Chain: L
Mutation: NULL
| >6GKD_L|Chain A, D[auth F], G[auth I], J[auth L], M[auth O], P[auth R]|Cystic fibrosis transmembrane conductance regulator|Homo sapiens (9606) SLTTTEVVMENVTAFWEEGGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMG |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| N: GLN1 ARG27 ALA28 SER30 TRP31 TYR32 VAL33 SER52 GLY53 ASN54 SER56 ARG57 SER100 THR101 TYR102 TYR104 TYR112 L: LYS503 TYR512 GLU514 TYR515 TYR517 ARG518 SER519 ILE521 LYS522 GLU527 ILE530 SER531 LYS532 ALA534 GLU535 LYS536 ASP537 ASN538 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
